Estrella Immunopharma (ESLA) Preferred Stock Liabilities (2021 - 2023)
Estrella Immunopharma (ESLA) posted quarterly Preferred Stock Liabilities of $9.8 million for Q2 2023, down 78.42% year-over-year from $45.2 million in Q2 2022, and up 2.26% quarter-over-quarter from $9.5 million in Q1 2023.
Estrella Immunopharma (ESLA) Preferred Stock Liabilities (2021 - 2023) Analysis & Trends
Estrella Immunopharma (ESLA) has reported Preferred Stock Liabilities for 3 consecutive years, with $9.8 million the latest figure, recorded in Q2 2023.
- In Q2 2023, Preferred Stock Liabilities fell 78.42% year-over-year to $9.8 million; the TTM figure through Jun 2023 stood at $9.8 million (down 78.42% YoY), while the FY2023 annual figure was $9.8 million, changed N/A from the prior year.
- Preferred Stock Liabilities advanced to $9.8 million in Q2 2023 per ESLA's latest filing, from $9.5 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $45.3 million in Q3 2022 and bottomed at $9.3 million in Q4 2022.
- Historically, Preferred Stock Liabilities has averaged $31.8 million across 3 years, with a median of $45.2 million in 2021.
- On a YoY basis, Preferred Stock Liabilities climbed as much as 0.29% in 2022 and fell as far as 79.36% in 2022.
- Estrella Immunopharma's Preferred Stock Liabilities stood at $45.2 million in 2021, then tumbled by 79.36% to $9.3 million in 2022, then grew by 4.56% to $9.8 million in 2023.
- Business Quant data shows ESLA's Preferred Stock Liabilities at $9.8 million in Q2 2023, $9.5 million in Q1 2023, and $9.3 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Estrella Immunopharma | 32.29 Mn | 32.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 9.75 Mn |
| Mar 31, 2023 | 9.54 Mn |
| Dec 31, 2022 | 9.33 Mn |
| Sep 30, 2022 | 45.32 Mn |
| Jun 30, 2022 | 45.19 Mn |
| Mar 31, 2022 | 45.19 Mn |
| Dec 31, 2021 | 45.19 Mn |
| Sep 30, 2021 | 45.19 Mn |